All In Biotech

Drug Trial Radar · NCT07738510

A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions

A Phase 2b, Multicenter, Open-Label, Dose-Escalation, and Randomized Dose-Optimization Study of Ofirnoflast (HT-6184) for the Treatment of Myelodysplastic Syndromes in Adults With Very Low- to Intermediate-Risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Oct 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Halia Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Parexel
First posted
Jul 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to two part. First, dose selection for dose optimization based on safety of ofirnoflast. Second, to evaluate the efficacy of ofirnoflast administered in the study population. The secondary objectives of this study are to evaluate the extended hematologic response to ofirnoflast, to assess the safety and tolerability of ofirnoflast during dose optimization, and to evaluate hematologic improvement with ofirnoflast treatment.

Conditions

  • Myelodysplastic Syndromes
  • Anemia

Interventions

  • OfirnoflastDrug

    tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose selection for dose optimizationTime frame: Days 1-28 of each Part 1 Cohort
  2. Evaluate the efficacy of ofirnoflast in to low- to intermediate-risk MDS who are transfusion dependentTime frame: Weeks 1-24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cleveland Clinic

    Cleveland, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.